support:13376277882 | tech@naturebios.com

N myc interactor/NMI Rabbit mAb [708P]Cat NO.: A73844

Western blot(SDS PAGE) analysis of extracts from A549 cells.Using N myc interactor/NMIRabbit mAb [708P] at dilution of 1:1000 incubated at 4℃ over night.

  • SizePriceIn stock
  • 50ul1280咨询客服
  • 100ul2380咨询客服
Order Datasheet

Product information

Protein names :NMI,NMI_HUMAN,N-myc-interactor

UniProtID :Q13287

MASS(da) :35,057

MW(kDa) :39 kDa

Form :Liquid

Purification :Protein A purification

Host :Rabbit

Isotype :IgG

sensitivity :Endogenous

Reactivity :Human

  • ApplicationDilution
  • 免疫印迹(WB)1:1000-2000
  • 免疫组化(IHC)1:100
  • 免疫荧光(ICC/IF) 1:100
  • The optimal dilutions should be determined by the end user

Specificity :Antibody is produced by immunizing animals with a synthetic peptide at the sequence of human N myc interactor/NMI

Storage :Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol. Shipped at 4°C. Store at-20°C or -80°C. Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

WB Positive detected :A549 cells

Function : Acts as a signaling pathway regulator involved in innate immune system response (PubMed:9989503, PubMed:26342464, PubMed:29038465, PubMed:29350881). In response to interleukin 2/IL2 and interferon IFN-gamma/IFNG, interacts with signal transducer and activator of transcription/STAT which activate the transcription of downstream genes involved in a multitude of signals for development and homeostasis (PubMed:9989503, PubMed:29377960). Enhances the recruitment of CBP/p300 coactivators to STAT1 and STAT5, resulting in increased STAT1- and STAT5-dependent transcription (PubMed:9989503). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator IFI35 to regulate immune response,the complex formation prevents proteasome-mediated degradation of IFI35 (PubMed:10779520, PubMed:10950963). In complex with IFI35, inhibits virus-triggered type I IFN-beta production when ubiquitinated by ubiquitin-protein ligase TRIM21 (PubMed:26342464). In complex with IFI35, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:29350881). Negatively regulates virus-triggered type I interferon/IFN production by inducing proteosome-dependent degradation of IRF7, a transcriptional regulator of type I IFN, thereby interfering with cellular antiviral responses (By similarity). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation, when actively released by macrophage to the extracellular space during cell injury or pathogen invasion (PubMed:29038465). Macrophage-secreted NMI activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 binding and activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines (PubMed:29038465)..

Tissue specificity :Expressed in adult spleen, liver, and kidney (PubMed:9781816). Expressed in fetal thymus, liver, placenta, spleen, lung, and kidney but not brain (PubMed:9781816). Expressed in macrophages (PubMed:29038465)..

Subcellular locationi :Cytoplasm. Nucleus. Secreted.

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v BSA, 1X TBST at 4°C overnight.